Compare Adecoagro SA (AGRO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Merck & Co., Inc. — how do they compare? Adecoagro SA trades at $9.24 (market cap $1.36B), while Merck & Co., Inc. trades at $133.06 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 236.6× Adecoagro SA's market cap, and Adecoagro SA pays the higher dividend (3.15%). Which is the better fit depends on your goals.
| AGRO | MRK | |
|---|---|---|
Market Cap | $1.36B | $321.77B |
Sector | Technology | Health |
52-Week High | $15.25 | $131.84 |
52-Week Low | $7.13 | $77.60 |
Enterprise Value | $3.39B | $368.53B |
Dividend Yield | 3.15% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.34, down 3.31% today, with a bearish technical signal from moving averages. The company reported mixed earnings, beating in Q3 2025 but missing in the last three quarters. Recent news highlights record adjusted EBITDA in Q2 2026 and an acquisition to expand operations. Valuation ratios like P/S of 0.71 and P/B of 0.77 suggest potential undervaluation, but low net income margins and negative recent EPS pose challenges.
The outlook is cautious; analyst consensus is mixed with 37.5% buy ratings. Upside potential exists from operational expansions and cost management, but risks include earnings volatility, high leverage from acquisitions, and commodity price exposure. Investors should weigh the low valuation against inconsistent profitability and macroeconomic headwinds.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
